ABOUT US PARTNER WITH US THERAPEUTIC AREAS PRODUCTS NEWS/PRESS SHARING CONTACT News/Press NEWS ZepzelcaTM (lurbinectedin) approved in United Arab Emirates (UAE) for the treatment of metastatic Small Cell Lung Cancer (SCLC) Immedica Pharma AB announces that the United Arab Emirates Ministry of Health and Prevention has approved ZepzelcaTM (lurbinectedin) – for the treatment of metastatic Small READ MORE » September 1, 2021 PRESS RELEASE Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the mid-twenties Immedica obtains exclusive commercialization rights in READ MORE » March 22, 2021 NEWS Immedica acquires the rights for additional Ophthalmology products for European countries Immedica Pharma AB (Immedica) has acquired rights from Novartis to five ophthalmology products involving indications for the treatment of glaucoma and inflammatory conditions of the READ MORE » March 8, 2021 NEWS Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries Stockholm, Hangzhou, December 30, 2020 – Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under READ MORE » December 31, 2020 NEWS Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc. Stockholm, November 6th, 2020 – Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated READ MORE » November 6, 2020 NEWS PharmaMar signs an agreement with Immedica PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries Madrid, READ MORE » April 29, 2020 NEWS Immedica speaker at the Nordic American Life Science Conference 2019 in New York City Commercialization of niche specialty care pharmaceutical products in Europe is a truly complex and multifaceted process. As a demonstration of its expertise in this area, READ MORE » December 9, 2019 NEWS Immedica starts to distribute Ravicti® and Ammonaps® in Europe and the Middle East from 1 January 2020 In December 2018, Immedica acquired the rights for the products Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), from Horizon Therapeutics in all territories outside North READ MORE » November 19, 2019 NEWS Immedica acquires the rights for Ophthalmology products for European countries Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the READ MORE » October 1, 2019 1 2 3 … 5 Privacy policy | Term of Use | Code of Conduct Immedica Pharma AB Norrtullsgatan 15 113 29 Stockholm Sweden E-mail: info@immedica.com Phone: +46(0)8 533 39 500 © 2021 All rights Reserved. Design by Immedica